Evaluation of Human Mesenchymal Stromal Cells as Carriers for the Delivery of Oncolytic HAdV-5 to Head and Neck Squamous Cell Carcinomas
Viruses · 2023
DOI: 10.3390/v15010218 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Robin Nilson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gene Therapy, University Medical Center Ulm, 89081 Ulm, Germany. Hauptthemen laut MEDLINE: Adenoviruses, Human, Head and Neck Neoplasms, Mesenchymal Stem Cells. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Federal Ministry of Education and Research, European Commission, Sanitätsakademie der Bundeswehr.
Abstract (Originalsprache)
Human multipotent mesenchymal stromal cells (hMSCs) are of significant therapeutic interest due to their ability to deliver oncolytic adenoviruses to tumors. This approach is also investigated for targeting head and neck squamous cell carcinomas (HNSCCs). HAdV-5-HexPos3, a recently reported capsid-modified vector based on human adenovirus type 5 (HAdV-5), showed strongly improved infection of both hMSCs and the HNSCC cell line UM-SCC-11B. Given that, we generated life cycle-unmodified and -modified replication-competent HAdV-5-HexPos3 vector variants and analyzed their replication within bone marrow- and adipose tissue-derived hMSCs. Efficient replication was detected for both life cycle-unmodified and -modified vectors. Moreover, we analyzed the migration of vector-carrying hMSCs toward different HNSCCs. Although migration of hMSCs to HNSCC cell lines was confirmed in vitro, no homing of hMSCs to HNSCC xenografts was observed in vivo in mice and in ovo in a chorioallantoic membrane model. Taken together, our data suggest that HAdV-5-HexPos3 is a potent candidate for hMSC-based oncolytic therapy of HNSCCs. However, it also emphasizes the importance of generating optimized in vivo models for the evaluation of hMSC as carrier cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gene Therapy, University Medical Center Ulm, 89081 Ulm, Germany.
- Institute for Transfusion Medicine, University Medical Center Ulm, 89081 Ulm, Germany.
- Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Donation Service, 89081 Ulm, Germany.
- Schlosspark Klinik Ludwigsburg, Privatklinik für Plastische und Ästhetische Chirurgie, 71638 Ludwigsburg, Germany.
- Schönheitsklinik Dr. Funk, 81739 München, Germany.
ORCID-Profile: Robin Nilson, Lea Krutzke, Markus Rojewski
Förderung
- Federal Ministry of Education and Research
- European Commission
- Sanitätsakademie der Bundeswehr
Zitieren
APA
Nilson, R., Krutzke, L., Wienen, F., Rojewski, M., Zeplin, P. H., Funk, W., Schrezenmeier, H., Kochanek, S., & Kritzinger, A. (2023). Evaluation of Human Mesenchymal Stromal Cells as Carriers for the Delivery of Oncolytic HAdV-5 to Head and Neck Squamous Cell Carcinomas. Viruses. https://doi.org/10.3390/v15010218
Vancouver
Nilson R, Krutzke L, Wienen F, Rojewski M, Zeplin PH, Funk W, et al. Evaluation of Human Mesenchymal Stromal Cells as Carriers for the Delivery of Oncolytic HAdV-5 to Head and Neck Squamous Cell Carcinomas. Viruses. 2023. doi:10.3390/v15010218
BibTeX
@article{Nilson2023,
author = {Nilson, Robin and Krutzke, Lea and Wienen, Frederik and Rojewski, Markus and Zeplin, Philip Helge and Funk, Wolfgang and Schrezenmeier, Hubert and Kochanek, Stefan and Kritzinger, Astrid},
title = {Evaluation of Human Mesenchymal Stromal Cells as Carriers for the Delivery of Oncolytic HAdV-5 to Head and Neck Squamous Cell Carcinomas},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15010218}
}
EUVIMED